分子生物学用酵素およびキット・試薬市場：製品別、用途別、エンドユーザー別、地域別、2024年～2031年

分子生物学用酵素およびキット・試薬市場の評価、2024年～2031年

強化された診断手順と個別化治療への需要の高まりが、分子生物学用酵素およびキット・試薬市場を牽引しています。Verified Market Researchのアナリストによると、分子生物学用酵素およびキット・試薬市場は、2023年の193億米ドルを下回り、予測期間2031年には694億米ドルの評価に達すると予測されます。

複雑な生物学的プロセスや疾病メカニズムの解明という世界の野心に後押しされたゲノムおよびプロテオミクス研究のブームが、分子生物学用酵素およびキット・試薬の需要を押し上げています。この需要の急増により、市場は2024年から2031年にかけてCAGR 17.35％で成長します。

分子生物学用酵素およびキット・試薬市場定義/概要

分子生物学用酵素およびキット・試薬は、DNA、RNA、タンパク質を操作・分析するための特殊な生化学ツールです。これらの道具には、DNAを増幅するDNAポリメラーゼ、特定の領域でDNAを切断する制限エンドヌクレアーゼ、DNA断片を結合させるリガーゼなどの酵素が含まれます。キットや試薬には、DNAを増幅するPCR（ポリメラーゼ連鎖反応）、DNAを分離するゲル電気泳動、DNAの塩基の並び順を決定する塩基配列決定などの分子生物学的手順を行うために必要な成分が含まれています。

さらに、これらの製品は遺伝子研究、医療診断、法医学分析、治療開発など様々な用途に不可欠であり、科学者や臨床医が病気の分子的原因を調査し、遺伝子変異を特定し、標的治療を開発することを可能にしています。

市場成長を促進する主な要因は？

ゲノミクスとプロテオミクス研究の急速な進歩が、分子生物学用酵素およびキット・試薬市場を大幅に押し上げました。シーケンス技術、CRISPRのような遺伝子編集技術、プロテオミクス研究における技術的進歩は、分子生物学的酵素の用途を広げ、市場拡大を促進しています。これらのブレークスルーは、正確な遺伝子変化やタンパク質の同定を可能にし、個別化医療やバイオテクノロジー・イノベーションの開発を促進しています。

個別化医療に対するニーズの高まりは、市場の重要な促進要因となっています。個別化医療では、遺伝子やプロテオミクスのデータを用いて特定の患者に合わせた治療を行うため、診断、治療標的の発見、医薬品開発において分子生物学的酵素やキットの使用が必要となります。この戦略は治療効果を高めると同時に副作用を軽減するため、ヘルスケアにおける分子生物学製品の利用を促進しています。

さらに、バイオ医薬品産業の台頭が分子生物学用酵素およびキット・試薬の需要を押し上げる主な要因となっています。これらのツールは、治療用タンパク質や核酸ベースの製品など、バイオ医薬品の研究、開発、製造に必要です。バイオ医薬品の研究開発費の増加と医薬品開発パイプラインにおける生物製剤の増加は、高品質の分子生物学製品を必要とする市場の拡大を後押ししています。

市場の成長を妨げる主な課題は何か？

酵素、キット、試薬は、信頼できる研究結果や臨床結果を提供するために、高い品質と再現性が求められます。しかし、製造工程のばらつき、原料の品質、保管条件のすべてが製品の一貫性に影響を及ぼします。この困難は、高い特異性と感度を必要とする分子生物学的アプリケーションの複雑化によってさらに悪化しています。これらの懸念に対処するためには、厳格な品質管理手順、プロトコルの標準化、バリデーション・プロセスが必要となるが、これらすべてが製造コストを上昇させ、これらの重要な機器の入手を制限し、市場の拡大を阻害します。

規制遵守は市場にとって大きな障壁となります。診断、投薬研究、治療用途に使用される製品は、米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの組織が定めた高い規制要件を遵守しなければならないです。承認取得には時間とコストがかかるため、製品リリースが遅れ、開発費用が増大し、市場開拓が制限されます。

目次

第1章 世界の分子生物学用酵素およびキット・試薬市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 分子生物学用酵素およびキット・試薬の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 分子生物学用酵素およびキット・試薬の世界市場：用途別

• 概要
• ポリメラーゼ連鎖反応（PCR）
• 塩基配列決定
• クローニング
• エピジェネティクス
• 制限酵素消化
• 合成生物学
• その他

第6章 分子生物学用酵素およびキット・試薬の世界市場：製品別

• 概要
• キットおよび試薬
• 酵素
• ポリメラーゼ
• リガーゼ
• その他

第7章 分子生物学用酵素およびキット・試薬の世界市場：エンドユーザー別

• 概要
• 学術・研究機関
• 製薬・バイオテクノロジー企業
• 病院・診断センター
• その他

第8章 分子生物学用酵素およびキット・試薬の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の分子生物学用酵素およびキット・試薬市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第10章 企業プロファイル

• Thermo Fisher Scientific Inc
• Illumina
• Qiagen
• Agilent Technologies
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Jena Bioscience GmbH
• Bioline Technologies
• Promega Corporation
• Rockland Immunochemicals Inc

第11章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

Molecular Biology Enzymes And Kits And Reagents Market Valuation - 2024-2031

The growing demand for enhanced diagnostic procedures and personalized treatment is driving the Molecular Biology Enzymes And Kits And Reagents Market. According to the analyst from Verified Market Research, the Molecular Biology Enzymes And Kits And Reagents Market is estimated to reach a valuation of USD 69.4 Billion over the forecast period 2031, subjugating around USD 19.3 Billion in 2023.

The boom in genomic and proteomic research efforts, fueled by the global ambition to comprehend complex biological processes and disease mechanisms, is driving up demand for molecular biology enzymes, kits, and reagents. This surge in demand enables the market to grow at a CAGR of 17.35% from 2024 to 2031.

Molecular Biology Enzymes And Kits And Reagents Market: Definition/ Overview

Molecular biology enzymes, kits, and reagents are specialized biochemical instruments for manipulating and analyzing DNA, RNA, and proteins. These tools include enzymes such as DNA polymerases, which amplify DNA, restriction endonucleases, which cut DNA at specified regions, and ligases, which combine DNA fragments, among others. Kits and reagents contain the components required to perform molecular biology procedures such as PCR (polymerase chain reaction) for DNA amplification, gel electrophoresis for DNA separation, and sequencing to determine the order of DNA bases.

Furthermore, these products are essential in various applications, including genetic research, medical diagnostics, forensic analysis, and therapeutic development, allowing scientists and clinicians to investigate the molecular causes of diseases, identify genetic variations, and develop targeted treatments.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Key Drivers that Bolster the Market Growth?

Rapid advances in genomics and proteomics research have considerably boosted the molecular biology enzymes, kits, and reagents market. Technological advancements in sequencing technologies, gene editing techniques such as CRISPR, and proteomics studies have broadened the applications of molecular biology enzymes, driving market expansion. These breakthroughs allow for precise genetic changes and protein identification, promoting the development of personalized medicine and biotechnological innovations.

The growing need for personalized medication has become a key market driver. Personalized medicine uses genetic and proteomic data to personalize treatments for specific patients, necessitating the use of molecular biology enzymes and kits in diagnostics, therapeutic target discovery, and drug development. This strategy improves therapy efficacy while reducing negative effects, encouraging the use of molecular biology products in healthcare.

Furthermore, the rise of the biopharmaceutical industry is a key factor driving demand for molecular biology enzymes, kits, and reagents. These tools are required for the study, development, and manufacture of biopharmaceuticals, such as therapeutic proteins and nucleic acid-based products. The increased expenditure in biopharmaceutical R&D, together with the growing number of biologics in the drug development pipeline, boosting the expansion of the market by needing high-quality molecular biology products.

What are the Primary Challenges Hindering the Growth of the Market?

Enzymes, kits, and reagents must be of high quality and reproducible to provide trustworthy research and clinical results. However, variability in the manufacturing process, raw material quality, and storage conditions all have an impact on product consistency. This difficulty is exacerbated by the growing complexity of molecular biology applications that require high specificity and sensitivity. Addressing these concerns necessitates stringent quality control procedures, protocol standardization, and validation processes, all of which raise manufacturing costs limit the availability of these vital instruments and inhibit market expansion.

Regulatory compliance presents a substantial barrier for the market. Products used in diagnostics, medication research, and therapeutic applications must adhere to high regulatory requirements established by organizations such as the United States Food and Medication Administration (FDA) and the European Medicines Agency. Obtaining approvals is time-consuming and expensive, delaying product releases, increasing development expenses and restricting market growth.

Category-Wise Acumens

Is Kits and Reagents Segment Dominating the Product Category?

According to VMR analysis, the kits and reagents segment is estimated to hold the largest market share in the product segment during the forecast period. Kits and reagents are required for a variety of molecular biology techniques, such as PCR, sequencing, cloning, and gene expression studies. Their adaptability and integration into multiple processes make them essential for ordinary and specialized research jobs. This broad applicability drives demand in a variety of disciplines, including academic research, clinical diagnostics, drug discovery, and development, contributing to their significant market share.

Kits and reagents are intended to simplify difficult molecular biology processes, lowering the time and technical skill required to conduct research. They frequently include pre-measured components and precise protocols to reduce errors and variability, improving repeatability and efficiency in the lab. This convenience, combined with the promise of consistent results, appeals to both seasoned researchers and those new to molecular biology, increasing adoption and market dominance.

Furthermore, the expanding emphasis on genomic research, driven by efforts to understand the genetic basis of diseases and develop personalized therapy, is resulting in a major increase in demand for high-quality kits and reagents. These items are essential for analyzing genetic data, identifying biomarkers, and creating tailored medicines. The growth of personalized medicine, which uses genetic information to customize therapies to specific patients, is increasing the demand for dependable and efficient kits and reagents, reinforcing their market position.

What are the Key Driving Forces for the Dominance of the PCR Application Segment?

The polymerase chain reaction (PCR) segment is estimated to dominate the Molecular Biology Enzymes And Kits And Reagents Market during the forecast period. PCR is a fundamental technique used in genetic and molecular research, as well as diagnostic applications such as infectious disease detection, cancer research, and genetic testing. The COVID-19 pandemic highlighted the critical role of PCR in quick testing and diagnostics, resulting in an unprecedented rise in demand for PCR kits and reagents. Its versatility and capacity to quickly amplify tiny pieces of DNA or RNA make it essential in both clinical and scientific settings.

Continuous advances in PCR technologies, such as real-time PCR (qPCR) and digital PCR (dPCR), have extended applications while improving sensitivity, specificity, and throughput. These advancements have simplified the application of PCR in a variety of disciplines, including personalized medicine, where it is utilized for patient stratification and disease progression monitoring, resulting in increased demand for PCR-related products.

Furthermore, the trend to precision medicine, as well as the growing demand for genetic testing for inherited illnesses, pharmacogenomics, and disease risk assessment, has accelerated the usage of PCR. PCR's capacity to detect specific DNA sequences makes it indispensable in various applications, adding to its market dominance. The growing awareness and acceptance of personalized healthcare solutions has resulted in increased investment in R&D activities in this area, which has fueled the rise of the PCR segment.

Country/Region-wise Acumens

Will Flourishing Healthcare Industry in North America Fuel this market?

According to VMR analyst, North America is estimated to dominate the Molecular Biology Enzymes And Kits And Reagents Market during the forecast period. The United States, in particular, provides substantial public and private financing for healthcare and biological research. The National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA), as well as private organizations and pharmaceutical firms, all offer significant financing for genetics, molecular biology, and related research. This financial support is driving up demand for molecular biology goods and helps to build the market.

Furthermore, North America is home to some of the world's largest biotechnology and pharmaceutical industries, which rely heavily on molecular biology enzymes, kits, and reagents. These industries deal with drug research, development, and diagnostic test development, all of which rely significantly on molecular biology techniques. The concentration of these businesses in North America, together with their innovation capabilities and market size, fueling the demand and development of advanced molecular biology products.

What are the Factors Leading to a Significant Share in Europe?

Europe has been in the lead in implementing precision medicine efforts and large-scale genomic projects. Countries such as the United Kingdom's 100,000 Genomes Project and France's National Genomic Medicine Strategy 2025 strive to integrate genomics into their healthcare systems. These projects necessitate considerable use of molecular biology products for DNA sequencing, PCR, and other genomic technologies, resulting in market expansion in the region.

Furthermore, European countries have made considerable investments in life sciences and biotechnology research, including both public and commercial funding. Horizon Europe, is the EU's primary funding program for research and innovation, with a budget of approximately €100 billion for the years 2021-2027, demonstrating the region's commitment to advancing scientific and technical research, including molecular biology. These expenditures increase the need for molecular biology enzymes, kits, and reagents required for cutting-edge research and development operations.

Competitive Landscape

The Molecular Biology Enzymes, and Kits and Reagents Market is characterized by a dynamic competitive landscape, driven by rapid advances in biotechnology and rising demand for molecular biology applications in a variety of industries, including healthcare, research, and diagnostics. The emphasis on precision and reliability, combined with severe regulatory requirements, influences the competitive strategies of businesses in this market.

Some of the prominent players operating in the Molecular Biology Enzymes And Kits And Reagents Market include:

Thermo Fisher Scientific Inc, Illumina, Qiagen, Agilent Technologies, F. Hoffmann-La Roche Ltd., Merck KGaA, Jena Bioscience GmbH, Bioline Technologies, Promega Corporation, Rockland Immunochemicals Inc, Takara Bio Inc, New England Biolabs Inc., Lucigen Corporation, GE Healthcare, PerkinElmer Inc., Bio-Rad Laboratories, Abbott Laboratories.

Latest Developments

In February 2024, Agilent Technologies announced the release of its new SureSelectXT Target Enrichment Kit for Illumina Sequencing, a comprehensive solution for targeted next-generation sequencing (NGS) library preparation.

In February 2024, Thermo Fisher Scientific announced a collaboration with Bio-Techne to create and commercialize new companion diagnostics for targeted cancer medicines.

In January 2024, Merck KGaA expanded its CRISPR portfolio with the introduction of new Cas9 enzymes and guide RNAs for gene editing applications.

In January 2024, Illumina announced the release of their new NovaSeq X Plus sequencing device, which provides higher throughput and accuracy for whole-genome and RNA sequencing applications.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET, BY APPLICATION

• 5.1 Overview
• 5.2 Polymerase Chain Reaction (PCR)
• 5.3 Sequencing
• 5.4 Cloning
• 5.5 Epigenetics
• 5.6 Restriction Digestion
• 5.7 Synthetic Biology
• 5.8 Others

6 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET, BY PRODUCT

• 6.1 Overview
• 6.2 Kits and Reagents
• 6.3 Enzymes
• 6.4 Polymerases
• 6.5 Ligases
• 6.6 Others

7 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET, BY END-USER

• 7.1 Overview
• 7.2 Academic and Research Institutes
• 7.3 Pharmaceutical and Biotechnology Companies
• 7.4 Hospitals and Diagnostic Centers
• 7.5 Others

8 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.3 Canada
  • 8.2.4 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Thermo Fisher Scientific Inc
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Illumina
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Qiagen
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Agilent Technologies
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 F. Hoffmann-La Roche Ltd.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Merck KGaA
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Jena Bioscience GmbH
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Bioline Technologies
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Promega Corporation
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Rockland Immunochemicals Inc
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research